Canada Lipid Disorder Therapeutics Market Analysis

Canada Lipid Disorder Therapeutics Market Executive Summary

Canada's Lipid Disorder Therapeutics Market is at around $808 Mn in 2023 and is projected to reach $1,857.8 Mn in 2030, exhibiting a CAGR of 12.63% during the forecast period.

Lipids refer to the major components of the body made up of hydrocarbons which play an important role in the formation and functioning of living cells. They are recognized as fat-type substances that are found inside the body as vitamins, oils, and waxes. They are often referred to as cholesterol and are necessary for the body's operation, particularly the heart. If not in balance, they could be harmful. Serious health problems may arise from having too much triglycerides and low-density lipoprotein (LDL) in the blood. Lipid disorders are among the health issues that are spreading the quickest in the globe. Lipid disorders can be treated with a variety of methods, such as lifestyle modifications, fibrates, cholesterol absorption inhibitors, statins, and bile acid sequestrants. Statins are drugs that stop a molecule from secreting that causes cholesterol to be produced. After that, the liver purges our blood of any cholesterol that is already there. Pravastatin, Simvastatin (Zocor), Rosuvastatin (Crestor), Fluvastatin (Lescol), and Atorvastatin (Lipitor). The amount of dietary cholesterol that is absorbed by our bodies is decreased by cholesterol absorption inhibitors, which are occasionally used in conjunction with statins.

According to the Canadian Journal of Cardiology, lipid disorders affect over 40% of Canadians aged 20 years and older. This prevalence underscores the importance of effective treatments and preventive measures in managing cardiovascular health. Over 60% of persons aged 60-79 are affected by the prevalence, which rises with age. Although women's risk increases after menopause, men often have greater rates than women. Important contributions are also played by lifestyle factors like food, exercise, and smoking. In order to reduce risks, the Canadian Cardiovascular Society supports early screening and risk-management techniques. The market therefore is driven by significant factors like the Increase in the Level of Triglyceride, Advancements in Therapeutics, Growing Healthcare Expenditure, and Infrastructure. However, Regulatory Hurdles, Adverse effects, and High cost of treatment restrict the growth and potential of the market.

Pfizer has been advancing its lipid-lowering therapies, including the development of Vupanorsen, an investigational antisense therapy targeting ANGPTL3, aimed at reducing triglycerides and LDL cholesterol levels.

Market Dynamics

Market Growth Drivers

Increase Triglyceride: The increasing prevalence of LDL-related diseases and the rise in triglyceride levels in the human body have a significant impact on the market for the treatment of lipid disorders. Working people globally are disproportionately affected by lipid disorders, which are brought on by bad lifestyle choices and behaviors such excessive drinking and smoking that raise cholesterol, inactivity, poor body development, and unsuccessful weight-control programs.

Advancements in Therapeutics: Recent advancements in lipid-lowering therapeutics, including the development of highly potent statins like Rosuvastatin and novel agents like PCSK9 inhibitors, have significantly improved treatment outcomes. These medications offer better efficacy and safety profiles, making them attractive options for managing lipid disorders. Ongoing research and development in this field continue to introduce new and improved treatments, enhancing the ability of healthcare providers to tailor therapies to individual patient needs, thus driving market growth​

Growing Healthcare Expenditure and Infrastructure: The extensive healthcare spending and strong healthcare system in Canada make cutting-edge lipid-lowering therapies widely available. The nation's healthcare system provides for the whole management of lipid problems, from initial diagnosis to continued care. Investments in healthcare services and infrastructure guarantee that patients receive top-notch care, which supports the expanding market for treatments for lipid disorders. Furthermore, funding for healthcare from both public and private sources provides the means to implement novel and efficient therapies.​

Market Restraints

Regulatory Hurdles: Although Canada's strict medication approval regulations guarantee patient safety, they also make market entry difficult. The market dynamics may be impacted by the protracted and intricate approval procedure, which may postpone the launch of new lipid-lowering treatments. Post-approval surveillance regulations also increase the expenses and complexity of doing business for pharmaceutical businesses.​

Adverse effects: Statins are examples of lipid-lowering drugs that frequently have adverse effects that include muscle soreness, liver damage, and elevated blood sugar levels that might result in diabetes. These negative effects may discourage patients from following recommended treatment plans, which would restrict the market's potential for expansion. For pharmaceutical companies and healthcare providers, managing these adverse effects and ensuring patient safety are crucial problems.

High cost of treatment: Biologics and gene therapies, two advanced lipid problem treatments, are expensive and hence not available to a large enough patient population. There may be inequities in treatment access due to the financial strain on individuals and healthcare systems. This financial barrier prevents the market from growing, which primarily affects individuals who are underinsured or without insurance.

Regulatory Landscape and Reimbursement Scenario

Several federal and local organizations oversee Canada's healthcare system, guaranteeing its accessibility, safety, and quality. Health Canada is in charge of national regulations, and provinces are in charge of their delivery and application. Regulatory agencies that keep an eye on pharmaceuticals, medical devices, and food safety include the Health Products and Food Branch (HPFB) and the Canadian Institutes of Health Research (CIHR). This all-encompassing framework seeks to promote innovation while preserving public health.

A combination of the public and private sectors is present in Canadian health policy. The public healthcare system guarantees that everyone has access to basic medical services and is primarily supported by taxes. But the private sector also contributes significantly, providing services like dental care, optometry, and prescription medications. Efficiency and accessibility are intended to be balanced by this hybrid approach.

Competitive Landscape

Key Players

Here are some of the major key players in the Canada Lipid Disorder Therapeutics Market:

• Sanofi
• Pfizer, Inc.
• GlaxoSmithKline plc
• Novartis AG
• Merck & Co., Inc.
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• Sun Pharmaceutical Industries Ltd.
• AbbVie, Inc.
• Viatris
• AstraZeneca PLC
• Dr. Reddy’s Laboratories Ltd.